David R Spigel Selected Research

David R Spigel Research Topics

Disease

82	Neoplasms (Cancer) 11/2022 - 04/2002
71	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 01/2003
28	Disease Progression 01/2022 - 04/2002
24	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 08/2003
14	Neutropenia 01/2021 - 06/2008
13	Carcinoma (Carcinomatosis) 10/2022 - 11/2005
12	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2008
11	Breast Neoplasms (Breast Cancer) 11/2021 - 04/2002
9	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2010
9	Fatigue 01/2020 - 12/2007
8	Diarrhea 12/2015 - 12/2007
7	Anemia 01/2021 - 01/2010
6	Melanoma (Melanoma, Malignant) 01/2021 - 09/2010
5	Brain Neoplasms (Brain Tumor) 01/2020 - 12/2009
5	Renal Cell Carcinoma (Grawitz Tumor) 10/2019 - 11/2005
5	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 07/2010
5	Exanthema (Rash) 09/2017 - 12/2007
5	Febrile Neutropenia 12/2014 - 11/2009
5	Hypersensitivity (Allergy) 10/2012 - 08/2007
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 05/2009
4	Body Weight (Weight, Body) 12/2018 - 06/2012
4	Neoplasm Metastasis (Metastasis) 12/2018 - 03/2006
4	Infections 01/2017 - 01/2012
4	Adenocarcinoma 04/2013 - 03/2006
4	Prostatic Neoplasms (Prostate Cancer) 06/2012 - 03/2006
3	Nausea 01/2020 - 11/2009
3	Vomiting 01/2020 - 11/2009
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2016 - 05/2009
3	Mucositis 02/2015 - 05/2009
2	Microsatellite Instability 01/2022 - 11/2021
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2020
2	Proteinuria 01/2018 - 11/2011
2	Hemorrhage 01/2018 - 02/2015
2	Pneumonia (Pneumonitis) 01/2017 - 04/2012

Drug/Important Bio-Agent (IBA)

34	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 10/2005
25	Bevacizumab (Avastin)FDA Link 01/2018 - 11/2005
21	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 10/2005
19	Docetaxel (Taxotere)FDA Link 01/2021 - 03/2006
18	PlatinumIBA 10/2022 - 09/2007
16	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 11/2005
15	NivolumabIBA 10/2022 - 06/2015
14	Gemcitabine FDA Link 01/2017 - 11/2005
13	Pemetrexed (MTA)FDA Link 12/2019 - 01/2010
11	ErbB Receptors (EGF Receptor)IBA 01/2018 - 11/2005
10	Monoclonal AntibodiesIBA 01/2021 - 12/2011
9	Pharmaceutical PreparationsIBA 01/2020 - 11/2005
8	Trastuzumab (Herceptin)FDA Link 01/2021 - 04/2002
7	atezolizumabIBA 10/2022 - 01/2018
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 08/2003
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2017
6	IpilimumabIBA 10/2022 - 05/2013
6	LigandsIBA 01/2022 - 06/2012
6	B7-H1 AntigenIBA 01/2021 - 10/2018
6	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 10/2005
6	Topotecan (Hycamtin)FDA LinkGeneric 12/2014 - 10/2005
5	Immune Checkpoint InhibitorsIBA 11/2022 - 06/2015
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 11/2005
4	Sorafenib (BAY 43-9006)FDA Link 11/2017 - 05/2010
4	Everolimus FDA Link 02/2015 - 05/2010
4	Cytotoxins (Cytolysins)IBA 10/2012 - 08/2006
4	Angiogenesis InhibitorsIBA 08/2012 - 01/2010
4	Hormones (Hormone)IBA 04/2011 - 03/2006
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2011 - 06/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2011 - 06/2008
3	durvalumabIBA 01/2022 - 12/2018
3	pembrolizumabIBA 01/2022 - 10/2020
3	pertuzumabIBA 01/2021 - 01/2018
3	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2017
3	amrubicinIBA 01/2018 - 05/2010
3	CrizotinibIBA 01/2018 - 05/2014
3	onartuzumabIBA 02/2017 - 11/2012
3	AnthracyclinesIBA 12/2014 - 04/2002
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2013 - 09/2008
3	Cetuximab (Erbitux)FDA Link 07/2010 - 08/2007
3	Rituximab (Mabthera)FDA Link 02/2010 - 03/2008
3	Gefitinib (Iressa)FDA Link 01/2010 - 09/2005
3	Imatinib Mesylate (Gleevec)FDA Link 11/2009 - 09/2007
3	taxaneIBA 08/2009 - 08/2006
3	Vinorelbine (Navelbine)FDA LinkGeneric 08/2009 - 09/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2012
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2015
2	130-nm albumin-bound paclitaxelIBA 01/2021 - 01/2018
2	hydroxide ionIBA 01/2021 - 10/2020
2	ceritinibIBA 01/2020 - 01/2017
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 05/2010
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2017
2	pazopanib FDA Link 01/2018 - 08/2012
2	necitumumabIBA 01/2018 - 01/2017
2	pegfilgrastim (Neulasta)FDA Link 01/2018 - 06/2008
2	Panitumumab (Vectibix)FDA Link 09/2017 - 01/2016

Therapy/Procedure

45	Therapeutics 10/2022 - 04/2002
39	Drug Therapy (Chemotherapy) 10/2022 - 04/2002
9	Radiotherapy 09/2017 - 12/2007
8	Immunotherapy 01/2022 - 09/2010
5	Chemoradiotherapy 01/2022 - 01/2010
4	Adjuvant Chemotherapy 11/2018 - 12/2007
4	Combination Drug Therapy (Combination Chemotherapy) 01/2018 - 11/2005
4	Combined Modality Therapy 04/2012 - 05/2009
2	Aftercare (After-Treatment) 02/2017 - 05/2010
2	Molecular Targeted Therapy 01/2017 - 04/2002